FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1554848350> ?p ?o ?g. }

• W1554848350 endingPage "441" @default.
• W1554848350 startingPage "435" @default.
• W1554848350 abstract "To investigate the inhibitory effect of sodium butyrate (NaB) on the proliferation of human bladder cancer cell lines and its synergetic effect with anticancer drugs in treating bladder cancer in vitro and in vivo.The inhibitory effects of NaB on human bladder cancer cell lines in vitro and the synergetic effect of NaB with mitomycin c, cisplatin (CDDP) and adriamycin were detected by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay. Hoechst staining and electron microscopy were used to observe morphology for apoptotic cells after NaB treatment. Fas, bcl-2 and caspase-3 were determined with flow cytometry. In vivo synergetic effects were detected in N-methyl-N-nitrosourea induced bladder cancer model rats.NaB significantly inhibited the growth of bladder cancer cell lines in a concentration and time dependent manner. Better results of tumor inhibition have been achieved when NaB was combined with CDDP, mitomycin c and adriamycin, rather than used alone. Furthermore, 2 h exposure to NaB can sensitize bladder cancer to chemotherapy agents. The Bcl-2 expression in bladder cancer cells is decreased and caspase-3 expression increased after NaB treatment. Intravesical application of NaB combined with CDDP can significantly inhibit tumor growth and progression.NaB has a direct anticancer effect and can markedly enhance the action of several chemotherapy agents. 2 h expose to NaB can also sensitize bladder cancer to anticancer drugs. NaB may be an excellent candidate agent for intravesical application in treating bladder cancer." @default.
• W1554848350 created "2016-06-24" @default.
• W1554848350 creator A5016610921 @default.
• W1554848350 creator A5044513573 @default.
• W1554848350 creator A5059490429 @default.
• W1554848350 creator A5082240190 @default.
• W1554848350 creator A5084461414 @default.
• W1554848350 creator A5088172355 @default.
• W1554848350 date "2008-03-26" @default.
• W1554848350 modified "2023-10-01" @default.
• W1554848350 title "Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs" @default.
• W1554848350 cites W2015538824 @default.
• W1554848350 cites W2015886726 @default.
• W1554848350 cites W2019568788 @default.
• W1554848350 cites W2054307692 @default.
• W1554848350 cites W2064602574 @default.
• W1554848350 cites W2066052727 @default.
• W1554848350 cites W2088783750 @default.
• W1554848350 cites W2095361625 @default.
• W1554848350 cites W2099378000 @default.
• W1554848350 cites W2104805076 @default.
• W1554848350 cites W2105695475 @default.
• W1554848350 cites W2116478273 @default.
• W1554848350 cites W2121296685 @default.
• W1554848350 cites W2134176478 @default.
• W1554848350 cites W2136494061 @default.
• W1554848350 cites W2167256217 @default.
• W1554848350 cites W2312877617 @default.
• W1554848350 doi "https://doi.org/10.1111/j.1442-2042.2008.02025.x" @default.
• W1554848350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18452462" @default.
• W1554848350 hasPublicationYear "2008" @default.
• W1554848350 type Work @default.
• W1554848350 sameAs 1554848350 @default.
• W1554848350 citedByCount "55" @default.
• W1554848350 countsByYear W15548483502012 @default.
• W1554848350 countsByYear W15548483502013 @default.
• W1554848350 countsByYear W15548483502014 @default.
• W1554848350 countsByYear W15548483502015 @default.
• W1554848350 countsByYear W15548483502016 @default.
• W1554848350 countsByYear W15548483502017 @default.
• W1554848350 countsByYear W15548483502018 @default.
• W1554848350 countsByYear W15548483502019 @default.
• W1554848350 countsByYear W15548483502020 @default.
• W1554848350 countsByYear W15548483502021 @default.
• W1554848350 countsByYear W15548483502022 @default.
• W1554848350 countsByYear W15548483502023 @default.
• W1554848350 crossrefType "journal-article" @default.
• W1554848350 hasAuthorship W1554848350A5016610921 @default.
• W1554848350 hasAuthorship W1554848350A5044513573 @default.
• W1554848350 hasAuthorship W1554848350A5059490429 @default.
• W1554848350 hasAuthorship W1554848350A5082240190 @default.
• W1554848350 hasAuthorship W1554848350A5084461414 @default.
• W1554848350 hasAuthorship W1554848350A5088172355 @default.
• W1554848350 hasConcept C121608353 @default.
• W1554848350 hasConcept C126322002 @default.
• W1554848350 hasConcept C141071460 @default.
• W1554848350 hasConcept C150903083 @default.
• W1554848350 hasConcept C185592680 @default.
• W1554848350 hasConcept C190283241 @default.
• W1554848350 hasConcept C207001950 @default.
• W1554848350 hasConcept C2776694085 @default.
• W1554848350 hasConcept C2778239845 @default.
• W1554848350 hasConcept C2778942008 @default.
• W1554848350 hasConcept C2779338040 @default.
• W1554848350 hasConcept C2780352672 @default.
• W1554848350 hasConcept C502942594 @default.
• W1554848350 hasConcept C54355233 @default.
• W1554848350 hasConcept C55493867 @default.
• W1554848350 hasConcept C62112901 @default.
• W1554848350 hasConcept C71924100 @default.
• W1554848350 hasConcept C81885089 @default.
• W1554848350 hasConcept C86803240 @default.
• W1554848350 hasConcept C96232424 @default.
• W1554848350 hasConcept C98274493 @default.
• W1554848350 hasConceptScore W1554848350C121608353 @default.
• W1554848350 hasConceptScore W1554848350C126322002 @default.
• W1554848350 hasConceptScore W1554848350C141071460 @default.
• W1554848350 hasConceptScore W1554848350C150903083 @default.
• W1554848350 hasConceptScore W1554848350C185592680 @default.
• W1554848350 hasConceptScore W1554848350C190283241 @default.
• W1554848350 hasConceptScore W1554848350C207001950 @default.
• W1554848350 hasConceptScore W1554848350C2776694085 @default.
• W1554848350 hasConceptScore W1554848350C2778239845 @default.
• W1554848350 hasConceptScore W1554848350C2778942008 @default.
• W1554848350 hasConceptScore W1554848350C2779338040 @default.
• W1554848350 hasConceptScore W1554848350C2780352672 @default.
• W1554848350 hasConceptScore W1554848350C502942594 @default.
• W1554848350 hasConceptScore W1554848350C54355233 @default.
• W1554848350 hasConceptScore W1554848350C55493867 @default.
• W1554848350 hasConceptScore W1554848350C62112901 @default.
• W1554848350 hasConceptScore W1554848350C71924100 @default.
• W1554848350 hasConceptScore W1554848350C81885089 @default.
• W1554848350 hasConceptScore W1554848350C86803240 @default.
• W1554848350 hasConceptScore W1554848350C96232424 @default.
• W1554848350 hasConceptScore W1554848350C98274493 @default.
• W1554848350 hasIssue "5" @default.
• W1554848350 hasLocation W15548483501 @default.
• W1554848350 hasLocation W15548483502 @default.

• next